RE: BOV

From: Liang Zhao Date: September 22, 2004 technical Source: cognigencorp.com
From: "Liang Zhao" zhao.80@osu.edu Subject: RE: [NMusers] BOV Date: Wed, September 22, 2004 2:59 pm Date: To: "Wang, Yaning" (more) Cc: "Wang, Yaning" Priority: Normal Options: View Full Header | View Printable Version I have the same doubt as Mike for Yaning's simplified scenario (with BOV is the same for all occasions). Based on my understanding, the design for both the simplified scenario and complex scenario is the same as Mike suggested. In this case, the BSV and BOV are not comfounded and they are all estimable. Think about the equation system CL11=CL+a1+b11 .... CLij=CL+ai+bij There are totally i*j (4*4=16) equations in this case, where i is number of subjects and j is the number of occasions. By adding constraint equations: a1+...+a4=0 b11+...+b1j=0 ... bi1+....+bij=0 in total we have i*j+1+j (21 in this case) equations. We know here CL, a1-ai, b11-bij are all unknowns and there are 21 of them. Solve the equation system we can get all of the values of unknowns. Since ai~N(0, BSV), i=1,..., t, t=4 in this example bij~N(0, BOV), j=1,..., r, r=4 in this example BSV and BOV can be further estimated by looking at ai's and bij's. one step further, since estimation of BSV and BOV does not require the full information of ai.s and bij's, there is big chance that the clinical design can be further reduced and you still get information about BSV and BOV. Even the algorithm to calculate BSV and BOV in NONMEM is carried out different, degree of freedoms that can be used for parameter estimations will not change, and I do think more effort should be put in this field of study for potential fractional clinical designs. If my derivation and reasoning is not making sense, please point out. It is a very stimulating discussion. Liang Zhao PhD Division of Pharmaceutics The Ohio State Univ.
Sep 20, 2004 Renee Ying Hong BOV
Sep 20, 2004 Nick Holford RE: BOV
Sep 20, 2004 Pravin RE: BOV
Sep 21, 2004 Pravin RE: BOV
Sep 21, 2004 Kenneth Kowalski RE: BOV
Sep 21, 2004 Nick Holford RE: BOV
Sep 21, 2004 Nick Holford RE: BOV
Sep 21, 2004 Kenneth Kowalski RE: BOV
Sep 21, 2004 Nick Holford RE: BOV
Sep 22, 2004 Fabrice Nollevaux RE: BOV
Sep 22, 2004 Kenneth Kowalski RE: BOV
Sep 22, 2004 Yaning Wang RE: BOV
Sep 22, 2004 Michael Fossler RE: BOV
Sep 22, 2004 Kenneth Kowalski RE: BOV
Sep 22, 2004 Yaning Wang RE: BOV
Sep 22, 2004 Liang Zhao RE: BOV
Sep 22, 2004 Liang Zhao RE: BOV
Sep 22, 2004 Michael Fossler RE: BOV
Sep 22, 2004 Liang Zhao RE: BOV
Sep 22, 2004 Mats Karlsson RE: BOV
Sep 22, 2004 Mats Karlsson RE: BOV
Sep 22, 2004 Qi Liu RE: BOV
Sep 22, 2004 Kenneth Kowalski RE: BOV
Sep 22, 2004 Nick Holford RE: BOV
Sep 22, 2004 Liang Zhao RE: BOV
Sep 22, 2004 Nick Holford RE: BOV
Sep 22, 2004 Mats Karlsson RE: BOV
Sep 22, 2004 Nick Holford RE: BOV
Sep 22, 2004 Yaning Wang RE: BOV
Sep 22, 2004 Qi Liu RE: BOV
Sep 22, 2004 Nick Holford RE: BOV
Sep 22, 2004 Yaning Wang RE: BOV
Sep 23, 2004 Kenneth Kowalski RE: BOV
Sep 23, 2004 Diane Mould RE: BOV
Sep 23, 2004 Mats Karlsson RE: BOV
Sep 23, 2004 Kenneth Kowalski RE: BOV
Sep 23, 2004 Liang Zhao RE: BOV
Sep 23, 2004 Mats Karlsson RE: BOV
Sep 23, 2004 Kenneth Kowalski RE: BOV
Sep 23, 2004 Nick Holford RE: BOV
Sep 23, 2004 Mats Karlsson RE: BOV
Sep 24, 2004 Kenneth Kowalski RE: BOV
Sep 24, 2004 Immanuel Freedman RE: BOV